x park taiwan

x park taiwan CONWAY, S.C. (AP) — Jayden Reid led South Florida with 14 points, including the game-winning jumper as time expired, and the Bulls defeated Wright State 73-72 on Sunday to claim third place at the Myrtle Beach Invitational tournament. Read this article for free: Already have an account? To continue reading, please subscribe: * CONWAY, S.C. (AP) — Jayden Reid led South Florida with 14 points, including the game-winning jumper as time expired, and the Bulls defeated Wright State 73-72 on Sunday to claim third place at the Myrtle Beach Invitational tournament. Read unlimited articles for free today: Already have an account? CONWAY, S.C. (AP) — Jayden Reid led South Florida with 14 points, including the game-winning jumper as time expired, and the Bulls defeated Wright State 73-72 on Sunday to claim third place at the Myrtle Beach Invitational tournament. Reid finished 6 of 9 from the field for the Bulls (4-3). Jamille Reynolds added 13 points while finishing 6 of 11 from the floor while he also had 14 rebounds and three blocks. Kobe Knox went 4 of 9 from the field (1 for 5 from 3-point range) to finish with 10 points. The Raiders (4-4) were led by Jack Doumbia, who posted 18 points and 10 rebounds. Solomon Callaghan added 15 points and seven rebounds for Wright State. Alex Huibregste finished with 12 points. Kasen Jennings scored seven points in the first half and South Florida went into the break trailing 34-32. Reynolds scored 10 second-half points. South Florida outscored Wright State by three points over the final half. NEXT UP South Florida plays Tuesday against Stetson at home, and Wright State hosts Air Force on Saturday. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. Advertisement

In conclusion, the focus on strengthening counter-cyclical adjustment measures beyond the norm and maintaining a moderately loose monetary policy stance underscores the government's commitment to fostering a more resilient and dynamic economy. By implementing a comprehensive set of policies and measures, policymakers are laying the foundation for a more prosperous and sustainable future.

Banque Cantonale Vaudoise Trims Holdings in IAMGOLD Co. (NYSE:IAG)But "Ming End: Wings of Abyss" is not just about looks - it also delivers when it comes to gameplay. Players can expect intense martial arts combat, with a variety of moves and special abilities to master. From powerful punches to graceful evasive maneuvers, players will have a range of options to choose from in battle. The game also features a robust leveling and progression system, allowing players to customize their characters to suit their playstyle.

Title: A-share Market Opens High Approaching 3500 Points with Major Positive Catalysts

Texans add much needed WR depth with addition of Diontae JohnsonFurthermore, the notion of countercyclical adjustment is underscored by the objective of stabilizing both the real estate and stock markets. These two sectors play a pivotal role in driving economic activity and investor confidence, making their stability essential for overall financial health. By implementing measures that address the unique dynamics of each market while considering their interrelatedness, policymakers can create a more resilient and balanced economic ecosystem.

As the days turned into weeks, the man encountered obstacles and temptations that tested his resolve. Despite the challenges, he remained committed to his goals and continued to document his journey for his followers. However, an unexpected twist derailed his progress and ultimately led to his downfall – he started hiding his face in all his posts and updates.Their clash with Real Madrid, one of the most successful clubs in the competition’s history, was billed as a battle of titans. But from the opening minutes of the match, it was clear that the reigning champions were a class above their opponents. With fluid passing, incisive attacking play, and rock-solid defense, they dismantled Real Madrid with ease, claiming a resounding victory that sent shockwaves through the football world.

Paolini’s Italy thump Slovakia to win Billie Jean King CupThe 26-year-old man charged in last week’s killing of UnitedHealthcare’s CEO in New York City made an appearance on Tuesday in a Pennsylvania courthouse . Police arrested Luigi Nicholas Mangione on Monday in last Wednesday's attack on Brian Thompson after they say a worker at a McDonald’s in Altoona, Pennsylvania, alerted authorities to a customer who resembled the suspected gunman. Mangione had on him a gun that investigators believe was used in last Wednesday’s attack, as well as writings expressing anger at corporate America, police said. As Mangione arrived at the courthouse Tuesday, he struggled with officers and shouted something that was partly unintelligible but referred to an “insult to the intelligence of the American people.” Mangione is being held without bail in Pennsylvania on charges of possession of an unlicensed firearm, forgery and providing false identification to police. Manhattan prosecutors have charged him with five counts, including murder, criminal possession of a weapon and criminal possession of a forged instrument. Here are some of the latest developments: During Tuesday's hearing, Mangione was denied bail. His attorney, Thomas Dickey, told the court that his client wants a hearing on the extradition issue. Mangione, wearing an orange jumpsuit, mostly stared straight ahead at the hearing, occasionally consulting papers, rocking in his chair, or looking back at the gallery. At one point, he began to speak to respond to the court discussion, but was quieted by his lawyer. In addition to a three-page, handwritten document that suggests he harbored “ill will toward corporate America,” NYPD Chief of Detectives Joseph Kenny said Monday that Mangione also had a ghost gun, a type of weapon that can be assembled at home and is difficult to trace. Officers questioned Mangione, who was acting suspiciously and carrying multiple fraudulent IDs, as well as a U.S. passport, New York Police Commissioner Jessica Tisch said. Officers also found a sound suppressor, or silencer, “consistent with the weapon used in the murder,” she said. He had clothing and a mask similar to those worn by the shooter and a fraudulent New Jersey ID matching one the suspect used to check into a New York City hostel before the shooting, the commissioner said. Kenny said Mangione was born and raised in Maryland, has ties to San Francisco and that his last known address is in Honolulu. Mangione, who was valedictorian of his Maryland prep school, earned undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania, a university spokesman told The Associated Press on Monday. Mangione comes from a prominent Maryland family. His grandfather Nick Mangione, who died in 2008, was a successful real estate developer. One of his best-known projects was Turf Valley Resort, a sprawling luxury retreat and conference center outside Baltimore that he purchased in 1978. Mangione likely was motivated by his anger with what he called “parasitic” health insurance companies and a disdain with corporate greed, said a law enforcement bulletin obtained by The Associated Press. He wrote that the U.S. has the most expensive healthcare system in the world and that the profits of major corporations continue to rise while “our life expectancy” does not, according to the bulletin, which was based on a review of the suspect’s hand-written notes and social media postings. The defendant appeared to view the targeted killing of the UnitedHealthcare CEO as a symbolic takedown and may have been inspired by “Unabomber” Ted Kaczynski, whom he called a “political revolutionary,” the document said. Police said the person who killed Thompson left a hostel on Manhattan's Upper West Side at 5:41 a.m. on Wednesday. Eleven minutes later, he was seen on surveillance video walking back and forth in front of the New York Hilton Midtown, wearing a distinctive backpack. At 6:44 a.m., he shot Thompson at a side entrance to the hotel, fled on foot, then climbed aboard a bicycle and within four minutes had entered Central Park, according to police. Another security camera recorded the gunman leaving the park near the American Museum of Natural History at 6:56 a.m. still on the bicycle but without the backpack, police said. After getting in a taxi, he headed north to a bus terminal near the George Washington Bridge, arriving at around 7:30 a.m. From there, the trail of video evidence runs cold. Police have not located video of the suspect exiting the building, leading them to believe he likely took a bus out of town. Police said they are still investigating the path the suspect took to Pennsylvania. “This just happened this morning," Kenny said. "We’ll be working, backtracking his steps from New York to Altoona, Pennsylvania,” Kenny said. Associated Press reporters Lea Skene, Matt O'Brien, Sean Murphy and Cedar Attanasio contributed to this report. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get the latest local business news delivered FREE to your inbox weekly.

Carolina Panthers quarterback Bryce Young was benched ahead of Week 3, but was thrust back into the starting role after Andy Dalton's injury. Since Young's return, the Panthers have defeated the New Orleans Saints, and New York Giants, and only lost a nail-biter to the Kansas City Chiefs. More News: Former Chiefs' Player's Family Says NFL Treats CTE Victims as 'Throwaways' Young was electric against the Chiefs, completing 21 of 35 passes, tallying 282 total yards, and no interceptions. Young finished the 30-27 loss to Kansas City with a 92.8 passer rating, his best of the season. Panthers head coach Dave Canales spoke on Young's weekly progress since his return to the starting role. "I don't have to make any statements, he's making it for himself," Canales said. "He's continuing to show us the progress we're looking for, bringing our skilled players to life. Talking about Bryce, it's the coaching staff, it's his teammates, he's showing us what he can do when he's out there." Despite losing to the Chiefs, Young proved his value to Carolina as he helped the team nearly beat a legitimate playoff contender. Only three teams have put up 25-plus points against the Kansas City defense: Joe Burrow and the Cincinnati Bengals, Josh Allen and the Buffalo Bills, and Young and the Panthers. The Panthers were down 20-6 at the half against the Chiefs, but Young helped the team in its efforts to take Kansas City to the brink. Compared to his first two starts of the season, Young looks like a completely different player in his recent starts. "When I see Bryce out there, I think 'Oh that's the Alabama Bryce,'" Panthers linebacker Trevin Wallace said. "Like that's cold. I love seeing him go make them plays. A lot of people I feel like doubted him a bit. Now he's showing the doubters wrong and I love that about Bryce." Young has made a steady progression in his fourth straight start since reclaiming the starting role in Carolina after Dalton's accident. Against the Giants in Munich, Young was 15 of 25 for 126 yards and a score. Against the Saints, Young led the Panthers on a game-winning touchdown drive. Originally, Canales said he would decide whether Young was the starting quarterback week-to-week. However, Young's recent performance changed Canales' tone when he was asked if the 23-year-old quarterback would get the start next week. "Absolutely," said Canales. For more on the NFL , head to Newsweek Sports .Commerce Bank decreased its position in shares of Zimmer Biomet Holdings, Inc. ( NYSE:ZBH – Free Report ) by 3.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,169 shares of the medical equipment provider’s stock after selling 700 shares during the period. Commerce Bank’s holdings in Zimmer Biomet were worth $2,393,000 as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors and hedge funds have also bought and sold shares of the company. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter worth $28,000. Bangor Savings Bank acquired a new stake in Zimmer Biomet in the third quarter worth about $31,000. Family Firm Inc. purchased a new stake in shares of Zimmer Biomet during the second quarter worth about $33,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Zimmer Biomet during the second quarter valued at about $43,000. Finally, Ridgewood Investments LLC purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $43,000. 88.89% of the stock is owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth Several research firms have weighed in on ZBH. BTIG Research dropped their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. UBS Group dropped their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a report on Thursday, August 8th. Royal Bank of Canada raised their target price on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Evercore ISI dropped their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Finally, Raymond James reduced their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $123.22. Zimmer Biomet Price Performance Shares of Zimmer Biomet stock opened at $110.22 on Friday. The firm has a market cap of $21.94 billion, a PE ratio of 20.95, a P/E/G ratio of 1.99 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a twelve month low of $101.47 and a twelve month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The business has a 50-day moving average price of $106.79 and a 200 day moving average price of $109.69. Zimmer Biomet ( NYSE:ZBH – Get Free Report ) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the company posted $1.65 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year. Zimmer Biomet Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio is currently 18.25%. Zimmer Biomet Profile ( Free Report ) Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. Recommended Stories Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter .

The minority SNP administration needs MSPs from at least one opposition party to either back or abstain in the vote on its spending plans in order to get them passed. The LibDem leader confirmed talks had taken place about the price of his party’s support – believed to include a £140 million ferry deal – but made it clear they would actively vote against any spending plans that promoted independence. Finance Secretary Shona Robison (below) will deliver the Scottish Government's Budget at Holyrood on December 4. Speaking to the BBC Scotland's Sunday Show, Cole-Hamilton said the public had sent the SNP a "clear message" in the recent General Election that they are "done with the constitution". He said: "I don’t see a circumstance where any Liberal Democrat could vote for a Budget that is clearly spending money on the constitution. READ MORE: Labour pledge to cut 'bulging benefits bill' to 'get Britain working' "I think that would be a massive misuse of public funds no matter how small. "We need every penny available spent on our schools, on our GP surgeries, on the mental health crisis." Cole-Hamilton (below) added: "The SNP will have to go a long way to persuade us, that whilst they might delete things like any independence spending from their budget that they won’t just go back to their old ways of spending any political oxygen on the constitution.” Asked by host Martin Geissler about whether LibDem MSPs might abstain, which would allow the Budget to pass despite containing money promoting independence, he said he would vote it down and "that is where we would be". Meanwhile, the Scottish Greens have said they will only back the Budget if no cuts to independence spending are made . We told how the Tories have demanded almost £1 billion in tax cuts from the Budget , although party leader Russell Findlay conceded that the plans were “unlikely” to be accepted. The SNP have been contacted for comment.Creative’s SoundBlaster G8 Is The Ultimate DAC For Gamers And Live Streamers

MALIBU, Calif. (AP) — The wildfire alert came in the middle of the night as some college students in Southern California were cramming for final exams and others were woken up in their dorms. But rather than run away from the impending blaze, some 3,000 students at Pepperdine University headed toward two buildings at the heart of the 830-acre (336 hectare) campus in coastal Malibu, California, to shelter in place. The protocol at the Christian university with picturesque views of the Pacific Ocean may seem to defy logic to those accustomed to scenes elsewhere in wildfire-prone California of thousands of residents evacuating fire zones in lengthy caravans of cars. For years, the university nestled in the foothills of the Santa Monica Mountains has had a special protocol due to its unique terrain and design that calls for students to be brought to a library and campus center where they can get food and water and have their basic needs met, said Michael Friel, a Pepperdine spokesperson. The school began preparing students and community members on what to do in case of a wildfire during new student orientation at the beginning of the academic year. When the fire broke out Monday night, school officials started communicating with students around 11 p.m. and activated the shelter-in-place protocol about two hours later, spreading the word through text messages, email, social media and by going door to door. “A lot of our students were woken up by a knock on the door, and we made sure they were aware of the conditions and we were able to get them out of harm’s way,” Friel said. The Franklin Fire quickly moved south, jumping over the famous Pacific Coast Highway and stretching to the coast, where large homes line the beach. Thousands of Southern California residents were under evacuation orders and warnings Tuesday with more than 8,100 homes and other structures under threat. County fire officials estimated that more than 3.5 square miles (9 square kilometers) of trees and dry brush had burned amid dangerous conditions fanned by dry, gusty Santa Ana winds that were expected to last into Wednesday. The cause of the fire was not immediately known. Ryan Song, a resident assistant at Pepperdine University, said he noticed the power went out at his dorm late Monday. When he looked out the window, he saw a huge pink glow. “I thought, ‘This is too bright,’ and it got bigger and bigger,” the 20-year-old junior said. “I immediately went outside and saw that it was a real fire.” Song and the other assistants went door to door to get students out. Most were calm and followed instructions, he said; a few who were scared rushed to their cars to get off campus. Song said he spent the next few hours racing back and forth in the dark between his dorm and the main campus to ensure no one was left behind. Pepperdine University officials said the campus was designed in the 1960s with fire safety in mind due to the region’s experience with wildfires. Buildings were clustered together and covered in stucco while roadways were constructed to make it easy for firefighters to get in, said Phil Phillips, the school’s executive vice president. During the 1990s, campus officials worked with Los Angeles County fire authorities to develop a safety plan, and authorities said the safest option for students would be to remain on campus. The school is diligent about brush clearance and has a plan to reduce smoke in shelter-in-place locations by taping shut doors and using air filters, he said. The nearby stretch of the Pacific Coast Highway can also become congested during an emergency, Phillips said, such as during the deadly Woolsey Fire in 2018. “What you don’t want is to be stuck,” said Phillips, who has been at the campus for three decades — including as a student — and said he has been through seven fires. “Protecting our students, providing for their safety is a moral obligation for us, so we take it really, really seriously.” On Tuesday, heavy smoke from the Franklin Fire, burning northeast of the school, billowed over the campus 29 miles (47 kilometers) west of Los Angeles, and classes were cancelled and final exams postponed. Firefighters had not contained any part of the blaze as of Tuesday afternoon. The campus was singed but no injuries were reported, and only one structure possibly was minimally damaged thanks to firefighters’ hard work and collaboration from students, faculty and others on campus, Friel said. Jim Gash, the college’s president, said the campus was no longer threatened on Tuesday afternoon. “I am grateful that through prayer, preparation, and cooperation, our Pepperdine community safely navigated the challenges encountered over the last 12 hours,” Gash said in a statement. “Our prayers continue to go out to the Malibu community.” ___ Taxin reported from Santa Ana, Calif. Associated Press writer Julie Watson in San Diego contributed to this report.Amie Just: Could the Big 12 be left out of CFP? And, is Ohio State better than Oregon?Prospera Financial Services Inc lowered its position in shares of Humana Inc. ( NYSE:HUM – Free Report ) by 12.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,493 shares of the insurance provider’s stock after selling 209 shares during the quarter. Prospera Financial Services Inc’s holdings in Humana were worth $474,000 as of its most recent SEC filing. A number of other hedge funds also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in shares of Humana in the third quarter worth approximately $701,000. S&CO Inc. boosted its holdings in Humana by 16.4% in the third quarter. S&CO Inc. now owns 33,760 shares of the insurance provider’s stock worth $10,693,000 after purchasing an additional 4,762 shares during the last quarter. Thrivent Financial for Lutherans grew its position in Humana by 55.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after purchasing an additional 214,535 shares during the period. AM Squared Ltd raised its stake in Humana by 200.0% during the 3rd quarter. AM Squared Ltd now owns 300 shares of the insurance provider’s stock valued at $95,000 after buying an additional 200 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its holdings in shares of Humana by 12.4% during the 3rd quarter. Mutual of America Capital Management LLC now owns 21,717 shares of the insurance provider’s stock valued at $6,879,000 after buying an additional 2,395 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of research analysts have weighed in on HUM shares. JPMorgan Chase & Co. increased their target price on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and raised their price objective for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a report on Thursday, October 3rd. Piper Sandler cut shares of Humana from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $392.00 to $274.00 in a research note on Thursday, October 3rd. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 price objective on shares of Humana in a research note on Tuesday, October 1st. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $315.86. Humana Trading Up 0.8 % Shares of HUM opened at $298.11 on Friday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $527.18. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $276.83 and its 200-day simple moving average is $330.68. The company has a market cap of $35.90 billion, a P/E ratio of 26.40, a P/E/G ratio of 2.33 and a beta of 0.52. Humana ( NYSE:HUM – Get Free Report ) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, analysts expect that Humana Inc. will post 15.86 EPS for the current year. Humana Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%. About Humana ( Free Report ) Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. Further Reading Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. ( NYSE:HUM – Free Report ). Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter .Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom’s macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). “While iopofosine I 131’s positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. “We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131’s substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success validates the platform’s ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company’s strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. “We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. “I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate TM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 cmaginn@blissbiohealth.com INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.com